JP2020526565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526565A5 JP2020526565A5 JP2020501515A JP2020501515A JP2020526565A5 JP 2020526565 A5 JP2020526565 A5 JP 2020526565A5 JP 2020501515 A JP2020501515 A JP 2020501515A JP 2020501515 A JP2020501515 A JP 2020501515A JP 2020526565 A5 JP2020526565 A5 JP 2020526565A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- nhco
- independently
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 208
- 125000003545 alkoxy group Chemical group 0.000 claims 51
- 125000000623 heterocyclic group Chemical group 0.000 claims 43
- 125000003342 alkenyl group Chemical group 0.000 claims 30
- 229910052736 halogen Inorganic materials 0.000 claims 30
- 150000002367 halogens Chemical class 0.000 claims 30
- 125000000304 alkynyl group Chemical group 0.000 claims 25
- 229910052760 oxygen Inorganic materials 0.000 claims 25
- 229910052799 carbon Inorganic materials 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 125000002837 carbocyclic group Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 9
- 229910004013 NO 2 Inorganic materials 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 102000000568 rho-Associated Kinases Human genes 0.000 claims 1
- 108010041788 rho-Associated Kinases Proteins 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 0 C*(C1CC2CC1)C2NC Chemical compound C*(C1CC2CC1)C2NC 0.000 description 3
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- JSIGUUUNVYUWQT-UHFFFAOYSA-N CNC1CCC1 Chemical compound CNC1CCC1 JSIGUUUNVYUWQT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531604P | 2017-07-12 | 2017-07-12 | |
| US62/531,604 | 2017-07-12 | ||
| PCT/US2018/041563 WO2019014304A1 (en) | 2017-07-12 | 2018-07-11 | SPIROHEPTANYL HYDANTOIDS AS ROCK INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526565A JP2020526565A (ja) | 2020-08-31 |
| JP2020526565A5 true JP2020526565A5 (enExample) | 2021-08-19 |
| JP7313331B2 JP7313331B2 (ja) | 2023-07-24 |
Family
ID=63145188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501515A Active JP7313331B2 (ja) | 2017-07-12 | 2018-07-11 | Ｒｏｃｋ阻害剤としてのスピロヘプタニルヒダントイン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11447487B2 (enExample) |
| EP (1) | EP3652167B1 (enExample) |
| JP (1) | JP7313331B2 (enExample) |
| KR (1) | KR102644889B1 (enExample) |
| CN (1) | CN110914257B (enExample) |
| ES (1) | ES2878054T3 (enExample) |
| WO (1) | WO2019014304A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2821877T3 (es) | 2016-07-07 | 2021-04-28 | Bristol Myers Squibb Co | Espirolactamas como inhibidores de ROCK |
| KR102511441B1 (ko) | 2016-11-30 | 2023-03-16 | 브리스톨-마이어스 스큅 컴퍼니 | 트리시클릭 Rho 키나제 억제제 |
| TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| JP7206253B2 (ja) | 2017-07-12 | 2023-01-17 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのフェニルアセトアミド |
| US12060341B2 (en) * | 2017-07-12 | 2024-08-13 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as ROCK inhibitors |
| KR102680160B1 (ko) | 2017-07-12 | 2024-06-28 | 브리스톨-마이어스 스큅 컴퍼니 | 심부전의 치료를 위한 rock의 5원-아미노헤테로사이클 및 5,6- 또는 6,6-원 비시클릭 아미노헤테로시클릭 억제제 |
| WO2019089868A1 (en) | 2017-11-03 | 2019-05-09 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
| AU2019377087B2 (en) | 2018-11-06 | 2025-03-06 | Cervello Therapeutics, Llc | Rock kinase inhibitors |
| US11248004B2 (en) | 2018-11-06 | 2022-02-15 | Cervello Therapeutics, Llc. | Substituted isoquinolines as rock kinase inhibitors |
| TW202122382A (zh) * | 2019-09-06 | 2021-06-16 | 日商小野藥品工業股份有限公司 | 乙內醯脲衍生物 |
| WO2023085369A1 (ja) | 2021-11-11 | 2023-05-19 | 学校法人同志社 | 角膜内皮細胞の凍結保存製剤およびその製造法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025150038A1 (en) * | 2024-01-09 | 2025-07-17 | Adama Makhteshim Ltd. | A method for separation of cis and trans isomers of hydantoin-containing spiro-compound from an isomeric mixture |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2653424A1 (en) | 2006-06-08 | 2007-12-13 | Ube Industries, Ltd. | Novel indazole derivative having spiro ring structure in side chain |
| CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| RU2457203C2 (ru) * | 2006-12-27 | 2012-07-27 | Санофи-Авентис | Замещенные циклоалкиламином производные изохинолона |
| CL2007003874A1 (es) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| UY33726A (es) | 2010-11-15 | 2012-06-29 | Abbott Lab | Inhibidores de nampt y rock |
| CA2898440A1 (en) | 2013-01-18 | 2014-07-24 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as rock inhibitors |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| JP6423372B2 (ja) | 2013-02-28 | 2018-11-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体 |
| EP3016950B1 (en) | 2013-07-02 | 2017-06-07 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| CN105492444B (zh) | 2013-07-02 | 2018-09-07 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| JP6633618B2 (ja) | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体 |
| WO2016112236A1 (en) | 2015-01-09 | 2016-07-14 | Bristol-Myers Squibb Company | Cyclic ureas as inhibitors of rock |
| WO2016144936A1 (en) | 2015-03-09 | 2016-09-15 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| AR107354A1 (es) | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
| JP6987792B2 (ja) | 2016-05-27 | 2022-01-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ｒｏｃｋ阻害剤としてのトリアゾロンおよびテトラゾロン |
| ES2821877T3 (es) | 2016-07-07 | 2021-04-28 | Bristol Myers Squibb Co | Espirolactamas como inhibidores de ROCK |
| ES2829550T3 (es) | 2016-07-07 | 2021-06-01 | Bristol Myers Squibb Co | Ureas cíclicas espiro-condensadas como inhibidores de ROCK |
| CN110049977B (zh) | 2016-07-07 | 2022-01-18 | 百时美施贵宝公司 | 作为强效和选择性rock抑制剂的内酰胺、环状脲和氨基甲酸酯及三唑酮衍生物 |
| KR102511441B1 (ko) | 2016-11-30 | 2023-03-16 | 브리스톨-마이어스 스큅 컴퍼니 | 트리시클릭 Rho 키나제 억제제 |
| TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| JP7206253B2 (ja) | 2017-07-12 | 2023-01-17 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのフェニルアセトアミド |
| KR102680160B1 (ko) | 2017-07-12 | 2024-06-28 | 브리스톨-마이어스 스큅 컴퍼니 | 심부전의 치료를 위한 rock의 5원-아미노헤테로사이클 및 5,6- 또는 6,6-원 비시클릭 아미노헤테로시클릭 억제제 |
| WO2019089868A1 (en) | 2017-11-03 | 2019-05-09 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
-
2018
- 2018-07-11 JP JP2020501515A patent/JP7313331B2/ja active Active
- 2018-07-11 CN CN201880046379.6A patent/CN110914257B/zh active Active
- 2018-07-11 KR KR1020207003731A patent/KR102644889B1/ko active Active
- 2018-07-11 US US16/629,784 patent/US11447487B2/en active Active
- 2018-07-11 EP EP18752653.8A patent/EP3652167B1/en active Active
- 2018-07-11 WO PCT/US2018/041563 patent/WO2019014304A1/en not_active Ceased
- 2018-07-11 ES ES18752653T patent/ES2878054T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526565A5 (enExample) | ||
| JP2019509978A5 (enExample) | ||
| JP2016505042A5 (enExample) | ||
| JP2017504642A5 (enExample) | ||
| JP2017525744A5 (enExample) | ||
| JP2014532070A5 (enExample) | ||
| JP2017504641A5 (enExample) | ||
| JP2020526547A5 (enExample) | ||
| JP6708130B2 (ja) | キノリン誘導体 | |
| CN115734966A (zh) | 杂环化合物及其用途 | |
| JP2014521701A5 (enExample) | ||
| JP2009524694A5 (enExample) | ||
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| JP2020533288A5 (enExample) | ||
| JP2007528379A5 (enExample) | ||
| IL298983B1 (en) | Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors | |
| JP2020527560A5 (enExample) | ||
| JP2007536224A5 (enExample) | ||
| JP2011520967A5 (enExample) | ||
| HRP20170784T1 (hr) | Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora | |
| JP2018538304A5 (enExample) | ||
| JP2010524896A5 (enExample) | ||
| CN106536509A (zh) | 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物 | |
| JP2018080173A5 (enExample) | ||
| JP2006507355A5 (enExample) |